Stock 2315 BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Equities

2315

CNE100005D27

End-of-day quote Hong Kong S.E.
Other stock markets
 06:00:00 2024-05-26 pm EDT 		5-day change 1st Jan Change
9.59 CNY +0.31% Intraday chart for Biocytogen Pharmaceuticals (Beijing) Co., Ltd. +0.42% -19.95%
May. 06 Biocytogen Enters into Evaluation and Potential Licensing Agreement with Biocopy for TCR-mimic Antibodies CI
Apr. 26 Biocytogen Pharmaceuticals' Loss Narrows in 2023 MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Biocytogen Enters into Evaluation and Potential Licensing Agreement with Biocopy for TCR-mimic Antibodies
CI
Biocytogen Pharmaceuticals' Loss Narrows in 2023
MT
Biocytogen Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Biocytogen Pharmaceuticals Co., Ltd. Enters Collaboration with ABL Bio Inc. to Develop New Bispecific Antibody-Drug Conjugates
CI
Biocytogen Pharmaceuticals Co., Ltd Announces Antibody Evaluation and Option Agreement with Gilead Sciences, Inc
CI
Biocytogen Pharmaceuticals Co., Ltd. Announces Launch of New Sub-Brand, RenBiologics
CI
Biocytogen Pharmaceuticals Co., Ltd. Enters into Bispecific Antibody Drug Conjugate Agreement with Radiance Biopharma
CI
Biocytogen Pharmaceuticals Co., Ltd. and CtM Biotech Co., Ltd Achieve Milestone Progress in Co-Developing A TCR-Mimic Antibody-Based Multi-Specific T Cell Engager Targeting WT1/HLA-A02
CI
Biocytogen Strikes Multi-Target Antibody Deal With Neurocrine Biosciences
MT
Biocytogen Pharmaceuticals Co., Ltd. Enters into Multi-Target Antibody Agreement with Neurocrine Biosciences
CI
Biocytogen Pharmaceuticals Co., Ltd. Announce an Antibody Evaluation, Option and License Agreement with Ona Therapeutics
CI
Biocytogen Pharmaceuticals Gets US Patent for RenMab Mice
MT
Biocytogen Pharmaceuticals' RenMice Series-Fully Human Antibody and TCR Mouse Models-Showcase Biocytogen's Capabilities to Innovate the Discovery of Biologic Drugs
CI
Myricx Enters into Antibody License Agreement with Biocytogen Pharmaceuticals Co., Ltd
CI
Biocytogen Pharmaceuticals Co., Ltd. Establishes Two Business Divisions to Distinguish Preclinical Models and Services from Antibody Drug R&D
CI
374,929,920 H Shares of Biocytogen Pharmaceuticals Co., Ltd. are subject to a Lock-Up Agreement Ending on 31-AUG-2023.
CI
Biocytogen Pharmaceuticals' Loss Narrows in H1; Shares Up 12%
MT
Biocytogen Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Biocytogen Pharmaceuticals Co., Ltd. Announces Project Integrum Achieves Milestone Progress, Accelerating Antibody Business Growth
CI
Biocytogen Pharmaceuticals Announces Grand Opening of Waltham, MA Facility
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 2315 Stock
  4. News Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
  5. Highlights